Table 3.
Exacerbations by study group
| Study groups | FP/SAL | BDP/FORM | BUD/FORM | FF/VI | FP/FORM | P value |
| Patients, n (%) | 996 (31.1) | 917 (28.6) | 802 (25.0) | 263 (8.2) | 225 (7.0) | |
| Follow-up period (1 year) | ||||||
| Exacerbations, % | 21.9 | 22.2 | 22.8 | 17.9* | 16.0* | 0.036 |
| Mean exacerbations | 0.4 (0.8) | 0.4 (0.8) | 0.4 (0.8) | 0.3 (0.8) | 0.3 (0.8) | 0.087 |
| Number of exacerbations/year, % | ||||||
| 0 | 78.1 | 78.3 | 77.2 | 82.1 | 84.0 | |
| 1 | 15.0 | 14.9 | 13.8 | 9.9 | 7.1 | |
| 2 | 2.9 | 2.6 | 5.5 | 1.9 | 5.3 | |
| 3+ | 4.0 | 4.1 | 3.5 | 6.1 | 3.6 | <0.001 |
| Patients with exacerbations, % | ||||||
| Mild-moderate | 20.1 | 21.7 | 22.2 | 17.5* | 16.0* | <0.001 |
| Severe (hospital admission) | 7.9 | 6.0 | 7.9 | 6.8 | 4.0* | <0.001 |
| Previous year (preindex) | ||||||
| Exacerbations, % | 28.7 | 28.1 | 28.9 | 25.5 | 25.3 | 0.698 |
| Mean exacerbations | 0.5 (0.9) | 0.5 (0.9) | 0.5 (0.9) | 0.5 (1.0) | 0.4 (0.9) | 0.973 |
| Number of exacerbations/year (%) | ||||||
| 0 | 71.3 | 71.9 | 71.1 | 74.5 | 74.7 | |
| 1 | 17.1 | 15.3 | 15.1 | 14.1 | 15.6 | |
| 2 | 5.9 | 8.4 | 9.1 | 3.0 | 2.7 | |
| 3+ | 5.7 | 4.5 | 4.7 | 8.4 | 7.1 | <0.001 |
| Patients with exacerbations, % | ||||||
| Mild-moderate | 27.5 | 27.4 | 28.7 | 24.1 | 25.4 | 0.111 |
| Severe (hospital admission) | 11.7 | 10.8 | 12.2 | 10.6 | 10.7 | 0.217 |
| Differences between the two periods, % | ||||||
| Exacerbations | −6.8 | −5.9 | −6.1 | −8.6* | −9.3* | 0.037 |
| Mild-moderate | −7.4 | −5.7 | −6.5 | −7.6 | −8.4 | 0.282 |
| Severe (hospital admission) | −3.8 | −4.8 | −4.4 | −5.8* | −6.7* | 0.044 |
Values expressed as percentage or mean (SD, standard deviation), p: statistical significance.
*Statistically significant results (effects observed > expected).
BDP/FORM, beclomethasone/formoterol; BUD/FORM, budesonide/formoterol; FF/VI, fluticasone furoate/vilanterol; FP/FORM, fluticasone propionate/formoterol; FP/SAL, fluticasone propionate /salmeterol.